Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kezar Life Sciences Inc KZR

Healthcare Biotechnology
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical... see more

Recent & Breaking News (NDAQ:KZR)

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Business Wire September 2, 2021

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

Business Wire August 23, 2021

Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates

Business Wire August 12, 2021

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

Business Wire July 8, 2021

Kezar Life Sciences Announces Formation of Clinical Advisory Committee

Business Wire June 8, 2021

Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021

Business Wire June 2, 2021

Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors

Business Wire June 1, 2021

Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference

Business Wire May 27, 2021

Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021

Business Wire May 26, 2021

Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates

Business Wire May 12, 2021

 Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work

Business Wire May 10, 2021

Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting

Business Wire April 10, 2021

Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates

Business Wire March 11, 2021

Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference

Business Wire February 25, 2021

Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference

Business Wire February 10, 2021

Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

Business Wire January 7, 2021

Kezar Life Sciences Added to the Nasdaq Biotechnology Index

Business Wire December 14, 2020

Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences

Business Wire November 12, 2020

Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates

Business Wire November 5, 2020

Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020

Business Wire November 5, 2020